Universal BCMA and CD19 CAR-T in Refractory Autoimmune Nervous System Diseases

Phase 1, open-label trial of BCMA-UCART and universal CD19 CAR-T in Neuromyelitis Optica Spectrum Disorder (NMOSD), myasthenia gravis (MG), multiple sclerosis (MS) and 1 more (3 arms), sponsored by Xuanwu Hospital. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Incidence of adverse events and severe adverse events at 12 months. Planned start Feb 2025; status: not yet recruiting.